Saltar a la navegació principal Saltar a la cerca Vés al contingut principal

The European Mouse Disease Clinic: A distributed phenotyping resource for studying human disease (EUMODIC)

Detalls del projecte

Descripció

As a first step towards a comprehensive functional annotation of the mouse genome, EUMODIC will undertake a primary phenotype assessment of up to 650 mouse mutant lines. In addition, a number of these mutant lines will be subject to a more in depth secondary phenotype assessment. The EUMODIC consortium is made up of 18 laboratories across Europe who are experts in the field of mouse functional genomics and phenotyping and have a track record of successful collaborative research in EUMORPHIA. The EUMODIC consortium will build on the work in the EUMORPHIA project that delivered a comprehensive database EMPReSS - of Standard Operating Procedures (SOPs) that can be used to determine the phenotype of a mouse. EUMODIC has developed a selection of these screens, EMPReSSslim, which is structured for comprehensive, primary, high throughput phenotyping of large numbers of mice. We will also adopt innovative approaches to the generation and assessment of cohorts of agematched mutants and controls for phenotyping. Primary phenotype assessment using EMPReSSslim will be undertaken in four large-scale phenotyping centres at the GSF, Germany; ICS, France; MRC Harwell, UK and the Sanger Institute, UK. Mutant lines will be made available from another EU initiative, the EUCOMM (European Conditional Mouse Mutagenesis) project which aims to produce conditional mutations in 20,000 mouse genes. EUMODIC will use these ES cells in the null configuration. A distributed network of centres with in depth expertise in a number of phenotyping domains will undertake more complex, secondary phenotyping screens and apply them to a subset of the mice which have shown interesting phenotypes in the primary screen. The partners will also develop technologies to refine EMPReSSslim and improve throughput of mouse phenotyping. A key element will be the continued development of bioinformatics resources to store the phenotype information and link them to existing database resources.
EstatusAcabat
Data efectiva d'inici i finalització1/02/0731/01/11

Socis col·laboradors

  • Medical Research Council (MRC) (Coordinador) (guia)
  • Centre Européen pour la Recherche en Biologie et Médecine - Groupement d'Intérêt Economique (Soci del projecte)
  • The Chancellor, Masters and Scholars of the University of Cambridge (Soci del projecte)
  • Centro Nacional de Investigaciones Oncológicas (Soci del projecte)
  • Consiglio Nazionale delle Ricerche (CNR) (Soci del projecte)
  • Centre National de la Recherche Scientifique (CNRS) (Soci del projecte)
  • European Molecular Biology Laboratory (EMBL) (Soci del projecte)
  • Ecole Normale Supérieure de Lyon (ENS de Lyon) (Soci del projecte)
  • Biomedical Sciences Research Center "Alexander Fleming" (BSRC Al. Fleming) (Soci del projecte)
  • Genome Research Ltd. (Soci del projecte)
  • GSF - Forschungszentrum für Umwelt und Gesundheit (Soci del projecte)
  • Helmholtz-Zentrum fuer Infektionsforschung GmbH (Soci del projecte)
  • Het Nederlands Kanker Instituut (Soci del projecte)
  • Tel Aviv University (Soci del projecte)
  • Fondazione Telethon (Soci del projecte)
  • University of Manchester (Soci del projecte)
  • University of Lausanne (UNIL) (Soci del projecte)

Finançament

  • Comissió Europea (CE): 12.000.000,00 €

Objectius de desenvolupament sostenible les Nacions Unides

El 2015, els estats membres de l’ONU van acordar 17 objectius de desenvolupament sostenible (ODS) internacionals per acabar amb la pobresa, protegir el planeta i garantir la prosperitat per a tothom. Aquest projecte persona contribueix als següents ODS:

  1. ODG 3 – Bona salut i benestar
    ODG 3 – Bona salut i benestar

Fingerprint

Explora els temes de recerca tractats en aquest projecte. Les etiquetes es generen en funció dels ajuts rebuts. Juntes formen un fingerprint únic.